Assessment of serum LDH and GGT level in breast cancer patients

Abstract

Background: Breast cancer is a type of cancer that originates in the cells of the breast tissue. The present study was conducted to assess serum LDH and Gamma GT in breast cancer patients.
Materials & Methods: 80 female subjects were divided into 2 groups of 40 each. Group I was cases with breast cancer who were further divided into premenopausal and post-menopausal. Group II was control subjects. Biochemical investigations like serum Lactate dehydrogenase, Gamma Glutamyl Transpeptidase, Alkaline phosphatase, liver enzymes (SGOT, SGPT, & ALP), and total proteins were calculated.
Results: The age group 20-45 years (premenopausal) had 18 patients in group I and 20 subjects in group II and >45 years had 22 post-menopausal patients in group I and 20 subjects in group II. The difference was non- significant (P> 0.05). Total protein (g/dl) in premenopausal, post-menopausal, and in group II subjects was 7.4, 8.6, 6.2 respectively. The mean albumin (g/dl) was 2.8, 3.0, and 2.4 respectively. The mean globulin (g/dl) levels were 4.6, 5.6, and 3.8 respectively. The mean LDH (U/L) level was 512.4, 536.4 and 290.4 respectively. The mean GGT (IU/L) level was 50.2, 84.6 and 24.6 respectively. The mean ALP (IU/L) was 122.5, 180.4, and 43.1 respectively. The mean SGOT (U/L) level was 62.1, 75.3 and 34.6. The mean SGPT (U/L) level was 68.5, 69.2, and 36.2 respectively.
Conclusion: The level of LDH, GGT, and ALP was significantly higher in breast cancer patients and hence, can be used as routine screening tests in all suspected carcinoma breast patients.